129 related articles for article (PubMed ID: 37625323)
1. Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma.
Sun T; Sun B; Cao Y; Liu J; Chen J; Liang B; Zheng C; Kan X
Biomed Pharmacother; 2023 Oct; 166():115351. PubMed ID: 37625323
[TBL] [Abstract][Full Text] [Related]
2. Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation.
Cao Y; Sun T; Sun B; Zhang G; Liu J; Liang B; Zheng C; Kan X
J Nanobiotechnology; 2023 Nov; 21(1):404. PubMed ID: 37919724
[TBL] [Abstract][Full Text] [Related]
3. Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma.
Wang F; Xu C; Li G; Lv P; Gu J
Exp Cell Res; 2021 Dec; 409(2):112910. PubMed ID: 34801560
[TBL] [Abstract][Full Text] [Related]
4. Radiofrequency hyperthermia enhances the effect of OK-432 for Hepatocellular carcinoma by activating of TLR4-cGAS-STING pathway.
Sun B; Zhang Q; Sun T; Liu J; Cao Y; Liang B; Zheng C; Kan X
Int Immunopharmacol; 2024 Mar; 130():111769. PubMed ID: 38442584
[TBL] [Abstract][Full Text] [Related]
5. Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation.
Shi ZR; Duan YX; Cui F; Wu ZJ; Li MP; Song PP; Peng QL; Ye WT; Yin KL; Kang MQ; Yu YX; Yang J; Tang W; Liao R
J Exp Clin Cancer Res; 2023 May; 42(1):133. PubMed ID: 37231509
[TBL] [Abstract][Full Text] [Related]
6. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy.
Zhao Z; Wu J; Liu X; Liang M; Zhou X; Ouyang S; Yao J; Wang J; Luo B
Cancer Lett; 2018 May; 421():73-81. PubMed ID: 29458142
[TBL] [Abstract][Full Text] [Related]
7. STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment.
Ao F; Li X; Tan Y; Jiang Z; Yang F; Guo J; Zhu Q; Chen Z; Zhou B; Zhang K; Li D
J Control Release; 2024 May; 369():296-308. PubMed ID: 38301925
[TBL] [Abstract][Full Text] [Related]
8. Perfluorocarbon nanodrug induced oxygen self-enriching sonodynamic therapy improves cancer immunotherapy after insufficient radiofrequency ablation.
Huang T; Wu W; Wu J; Tan Y; Zhang M; Long H; Guo H; Zhang X; Zhou W; Zhang Q; Xie X; Xu M; Zhang C
Front Immunol; 2023; 14():1124152. PubMed ID: 37051250
[TBL] [Abstract][Full Text] [Related]
9. Size-Tunable Nanoregulator-Based Radiofrequency Ablation Suppresses MDSCs and Their Compensatory Immune Evasion in Hepatocellular Carcinoma.
Tang Y; Shu Z; Zhu M; Li S; Ling Y; Fu Y; Hu Z; Wang J; Yang Z; Liao J; Xu L; Yu M; Peng Z
Adv Healthc Mater; 2023 Dec; 12(30):e2302013. PubMed ID: 37665720
[TBL] [Abstract][Full Text] [Related]
10. The HSP90 inhibitor, XL888, enhanced cell apoptosis via downregulating STAT3 after insufficient radiofrequency ablation in hepatocellular carcinoma.
Sun C; Bai M; Ke W; Wang X; Zhao X; Lu Z
Life Sci; 2021 Oct; 282():119762. PubMed ID: 34186047
[TBL] [Abstract][Full Text] [Related]
11. Insufficient radiofrequency ablation-induced autophagy contributes to the rapid progression of residual hepatocellular carcinoma through the HIF-1α/BNIP3 signaling pathway.
Xu WL; Wang SH; Sun WB; Gao J; Ding XM; Kong J; Xu L; Ke S
BMB Rep; 2019 Apr; 52(4):277-282. PubMed ID: 30940322
[TBL] [Abstract][Full Text] [Related]
12. Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression.
Chen X; Huang Y; Chen H; Chen Z; Chen J; Wang H; Li D; Su Z
J Nanobiotechnology; 2022 Jan; 20(1):34. PubMed ID: 35033089
[TBL] [Abstract][Full Text] [Related]
13. In vivo immunological antitumor effect of OK-432-stimulated dendritic cell transfer after radiofrequency ablation.
Nakagawa H; Mizukoshi E; Iida N; Terashima T; Kitahara M; Marukawa Y; Kitamura K; Nakamoto Y; Hiroishi K; Imawari M; Kaneko S
Cancer Immunol Immunother; 2014 Apr; 63(4):347-56. PubMed ID: 24384836
[TBL] [Abstract][Full Text] [Related]
14. Insufficient radiofrequency ablation promotes hepatocellular carcinoma cell progression via autophagy and the CD133 feedback loop.
Wang X; Deng Q; Feng K; Chen S; Jiang J; Xia F; Ma K; Bie P
Oncol Rep; 2018 Jul; 40(1):241-251. PubMed ID: 29749472
[TBL] [Abstract][Full Text] [Related]
15. Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation.
Zeng X; Liao G; Li S; Liu H; Zhao X; Li S; Lei K; Zhu S; Chen Z; Zhao Y; Ren X; Su T; Cheng AS; Peng S; Lin S; Wang J; Chen S; Kuang M
Hepatology; 2023 Apr; 77(4):1122-1138. PubMed ID: 35598182
[TBL] [Abstract][Full Text] [Related]
16. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy.
Shi L; Wang J; Ding N; Zhang Y; Zhu Y; Dong S; Wang X; Peng C; Zhou C; Zhou L; Li X; Shi H; Wu W; Long X; Wu C; Liao W
Nat Commun; 2019 Nov; 10(1):5421. PubMed ID: 31780645
[TBL] [Abstract][Full Text] [Related]
17. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response.
Qi X; Yang M; Ma L; Sauer M; Avella D; Kaifi JT; Bryan J; Cheng K; Staveley-O'Carroll KF; Kimchi ET; Li G
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115942
[TBL] [Abstract][Full Text] [Related]
18. GSDME has prognostic and immunotherapeutic significance in residual hepatocellular carcinoma after insufficient radiofrequency ablation.
Liang X; Liu Q; Zhu S; Li Z; Chen H; Su Z
Transl Oncol; 2024 Jan; 39():101796. PubMed ID: 37862939
[TBL] [Abstract][Full Text] [Related]
19. Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6-Methyladenosine mRNA Methylation-Dependent Mechanism.
Su T; Huang M; Liao J; Lin S; Yu P; Yang J; Cai Y; Zhu S; Xu L; Peng Z; Peng S; Chen S; Kuang M
Hepatology; 2021 Sep; 74(3):1339-1356. PubMed ID: 33638162
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
Wang H; He X; Fang D; Wang X; Guan J; Shi ZW; Chen X
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101853. PubMed ID: 34923183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
